Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

10 Things For Pfizer's New CEO To Worry About

16 Oct 2018

• By Bridget Silverman

Albert Bourla will face opportunities and potential pitfalls.

Albert Bourla — Albert Bourla takes the CEO reins at Pfizer Jan. 1.

Related Content

From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive

07 Sep 2018

Pfizer Eyes First-To-Market Opportunity In Alopecia

18 Sep 2018

Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up

12 Sep 2018

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

12 Sep 2018

Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market

12 Sep 2018

Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?

27 Sep 2018

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain

16 Aug 2018

Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer

24 Aug 2018

Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products

02 Oct 2018

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

11 Apr 2018

UK Changes Approach To Trials In Patients With Prior ATMP Therapy

29 Aug 2018

Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects

03 Jun 2018

Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway

07 May 2018

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

01 Oct 2018

Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J

23 Sep 2018

Pfizer Remains Flexible On Consumer Health In Restructuring

01 Aug 2018

Pfizer Agrees To Oversight Of Charitable Assistance Programs In DOJ Settlement

25 May 2018

Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

01 Aug 2018

Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi

16 Jul 2018

Pfizer Deals Consumer Health Its Own Hand, Plays Waiting Game For Bids

11 Jul 2018

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

11 Jul 2018

Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

14 Dec 2017

Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?

18 Jul 2018

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

30 May 2018

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

22 May 2018

Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

09 Jan 2018

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Eli Lilly and Company

Incyte Corporation

AstraZeneca PLC

Novartis AG

Amgen, Inc.

Advanced Accelerator Applications SA

Sun Pharmaceutical Industries Ltd.

Array BioPharma, Inc.

Johnson & Johnson

Merck KGaA

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Gilead Sciences, Inc.

Bristol Myers Squibb Company

Regeneron Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Spark Therapeutics, Inc.

Additional Topics

United States Strategy Companies Drug Review Commercial BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.